CRH starts a stress chain that ends, several steps later, in cortisol. They are different chemicals made in different places, and mixing them up is why so much stress-testing and so many CRH-targeted drugs have not delivered what they promised.
Part 12 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- CRH, ACTH, and cortisol are three different signals made in three different places. CRH starts the chain, ACTH is the middle step, and cortisol is the end result.
- CRH also acts as a local brain signal on its own, separate from the hormone chain, and that local signal will not show up in a blood cortisol test.
- “Adrenal fatigue” is not a validated medical condition, and no blood or saliva test can diagnose it. Real fatigue is common and deserves a real evaluation.
- Drug companies spent decades testing medicines that blocked one CRH receptor for depression, anxiety, PTSD, and alcohol cravings. The biology looked promising. The clinical trials were negative.
- One CRH-receptor blocker is FDA-approved, but for a hormone condition, not a psychiatric one, and its existence does not change what the failed psychiatric trials found.
- Suddenly stopping a steroid medicine after sustained use, or a true adrenal crisis, are medical emergencies. This article gives no taper plan.
The short answer
Corticotropin-releasing hormone, or CRH, is a brain chemical made mainly in the hypothalamus. It starts one of the body’s main stress-response chains: the hypothalamus releases CRH, which tells the pituitary gland to release a hormone called ACTH, which tells the adrenal glands to release cortisol. Cortisol then acts across the body and feeds information back to the brain.
That is three different chemicals in three different places, not one signal with three names. CRH also works separately, inside local brain circuits like the amygdala, where it can change arousal or how threat gets learned. That local brain signal does not always match what a blood cortisol test shows, because a blood test only sees the far end of the chain.
The two main receptors CRH acts on are called CRF1 and CRF2. For years, researchers hoped that blocking CRF1 would treat depression, generalized anxiety disorder, PTSD, and alcohol-related craving, because animal research made the receptor look like a clear target for chronic stress. Direct CRF1-blocking drugs did change laboratory stress measures in human trials. But those same trials, across several different drugs and several different conditions, did not show the clinical benefit researchers were hoping for. Biology can be real even when a specific drug strategy built on it does not work out.
CRH is made inside certain hypothalamic neurons, cut from a larger precursor molecule, and packaged for release. In a region called the paraventricular nucleus, CRH neurons send their endings to a spot at the base of the brain, where CRH enters a short, local blood-vessel system that carries it directly to the pituitary gland.
At the pituitary, CRH activates CRF1 receptors on cells called corticotrophs, which release ACTH, adrenocorticotropic hormone, into the main bloodstream. ACTH travels to the adrenal glands, which sit on top of the kidneys, and triggers the release of cortisol, a steroid hormone that affects metabolism, immune activity, blood vessels, attention, and memory. Cortisol then feeds back to the pituitary and brain to help regulate the whole chain.
The literal path is: hypothalamic CRH, then pituitary ACTH, then adrenal cortisol, then feedback to the brain and pituitary. This chain moves in pulses and follows a daily rhythm, and it can be moved by sleep, waking, pain, infection, food, exercise, medicine, trauma, age, pregnancy, and even the time of day a sample is drawn.1
CRH’s second job, working as a local signal inside brain circuits like the amygdala, happens outside this endocrine relay entirely. Think of the whole system as a relay race: CRH hands off to ACTH, and ACTH hands off to cortisol. Each runner also receives separate inputs along the way, and CRH runs a second race entirely, inside local brain circuits, that never gets handed off to cortisol at all.
Meet CRF1 and CRF2
| Receptor or target | What it does, where it matters, and why you might care |
|---|---|
| CRF1 | What it does: Usually increases activity inside the cell it sits on. Where it matters: Pituitary, cortex, amygdala, hippocampus. Why you might care: Starts ACTH release at the pituitary; it was the main target of the psychiatric drugs that were tested and failed. |
| CRF2 | What it does: A related receptor with several forms. Where it matters: Brain, heart, blood vessels, gut. Why you might care: May play a role in stress recovery, appetite, and body regulation, but its psychiatric relevance in humans is not settled. |
| Urocortins 1, 2, and 3 | What it does: Related natural signals that also activate CRF receptors. Where it matters: Brain and other body tissues. Why you might care: Show that CRH does not act alone on this receptor family; no routine psychiatric medicine targets them. |
| CRH-binding protein | What it does: Binds CRH-family signals and changes how much reaches a receptor. Where it matters: Brain, pituitary, blood. Why you might care: Helps explain why the amount of CRH released does not translate directly into a fixed amount of receptor activation. |
If CRF1 were simply “the anxiety receptor,” blocking it should have been a reliable treatment. That is not what the human trials found, and the results below explain why that label is too simple.
Why CRF1 blockers looked promising and then failed
Researchers tested several different CRF1-blocking drugs across several different conditions, and it is worth naming them, because the pattern across all of them is the real lesson here.
An early drug called R121919 showed some improvement in a small depression study, but the study had no placebo group, so it could not confirm whether the drug itself was responsible. A more rigorous six-week randomized trial of CP-316,311 did not outperform placebo in major depression.4 Pexacerfont was tested in two conditions: it did not beat placebo for generalized anxiety disorder, and in a separate trial in people with alcohol dependence, it showed no effect on craving or anxiety either.37 GSK561679 was tested in 128 women with PTSD and showed no advantage over placebo on the main outcome.5
The clearest example of the gap between hitting a biological target and helping a person is a drug called verucerfont, tested for stress-related alcohol craving. Verucerfont changed the hormone stress response the researchers were measuring. It genuinely reached its target and changed the biology. But it did not reduce stress-induced alcohol craving, which was the actual outcome that mattered.6 The target moved. The outcome did not.
This is why a drug can succeed at reaching a receptor and changing a hormone measurement, and still fail at the step that actually matters to a person’s life. Reaching a target, changing a lab value, and improving symptoms are three separate questions, and a drug can answer the first two and still miss the third.
What about “adrenal fatigue”?
This comes up constantly, so it deserves a direct answer.
“Adrenal fatigue” is not a validated medical condition.910 No blood or saliva test, including the commercial panels sold for this purpose, can diagnose it, because there is no established biological definition for those tests to confirm.9 That does not mean fatigue itself is not real. Fatigue is common and can come from sleep disorders, anemia, thyroid disease, infection, pain, depression, medication, substance use, or a genuine endocrine illness that does have validated tests, like Cushing syndrome or true adrenal insufficiency. Fatigue does not deserve to be dismissed. A saliva cortisol panel is simply not the tool that answers the question.
What each medicine actually touches
No routine FDA-approved psychiatric medicine directly targets CRH or its receptors. But one CRF1-blocking drug is approved, and it is worth explaining exactly what it does and does not tell us.
Crinecerfont, sold as Crenessity, is a CRF1 blocker approved by the FDA in December 2024 for classic congenital adrenal hyperplasia, a hormone condition where it lowers ACTH-driven adrenal androgen production.11 It has no psychiatric indication. Its approval does not undo or rescue the failed psychiatric trials described above. If anything, it sharpens the argument: CRF1 blockade can genuinely work as a treatment when a condition is directly driven by excess CRF1-and-ACTH signaling, the way congenital adrenal hyperplasia is. Depression, generalized anxiety, PTSD, and alcohol craving are not driven that same direct way, which is likely part of why blocking the same receptor did not help those conditions the way it helps this one.
| Medicine | What it does directly, studied for or approved for, and main finding or tradeoff |
|---|---|
| R121919 | What it does directly: CRF1 blocker. Studied for or approved for: Early depression research. Main finding or tradeoff: Small open-label study suggested improvement, but with no placebo group to confirm it; never approved. |
| CP-316,311 | What it does directly: CRF1 blocker. Studied for or approved for: Major depression. Main finding or tradeoff: Did not outperform placebo in a six-week randomized trial; never approved. |
| Pexacerfont | What it does directly: CRF1 blocker. Studied for or approved for: Generalized anxiety disorder; alcohol dependence. Main finding or tradeoff: Did not beat placebo for anxiety; a separate trial found no effect on alcohol craving either; never approved. |
| GSK561679 | What it does directly: CRF1 blocker. Studied for or approved for: PTSD in women. Main finding or tradeoff: No advantage over placebo in a 128-person randomized trial; never approved. |
| Verucerfont | What it does directly: CRF1 blocker. Studied for or approved for: Stress-related alcohol craving. Main finding or tradeoff: Changed the hormone stress response but did not reduce craving; never approved. |
| Crinecerfont (Crenessity) | What it does directly: CRF1 blocker. Studied for or approved for: Congenital adrenal hyperplasia. Main finding or tradeoff: FDA-approved, but for a hormone condition, not a psychiatric one; no psychiatric indication exists. |
Mifepristone, dexamethasone, and cosyntropin act at other points along this same hormone chain, but none of them is a direct CRH-receptor psychiatric medicine either. Sharing a chain does not make every drug on it interchangeable.
Can CRH or the HPA axis be measured?
Parts of this system can be measured, but each test answers a narrow question, not a global one.
Blood ACTH measures pituitary output and needs careful collection because it moves in pulses. Blood or saliva cortisol measures the downstream adrenal hormone, not CRH, and is affected by timing, waking, sleep, food, illness, medication, and how the sample is collected. Urinary cortisol collected over a longer period, and a test called dexamethasone suppression, can be useful in a defined endocrine workup, but a group research result does not diagnose an individual’s mental health. A cerebrospinal-fluid CRH measurement gets closer to the brain than blood does, but it is invasive, still cannot show release at one specific location, and has no established role in choosing a psychiatric medicine.
None of these tests, alone or together, can diagnose “adrenal fatigue” or show that someone has too much CRH in their brain. Real hormone diseases need validated medical testing ordered for a specific clinical reason, not a commercial panel marketed directly to consumers.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: the timing of sleep changes, fatigue, anxiety, appetite change, dizziness, and how any of this affects your daily function. Note medication changes, illness, and caffeine, alcohol, or cannabis use alongside it.
Call the prescriber or pharmacist promptly: for persistent new weakness, dizziness on standing, a marked mood or sleep change after starting or changing a steroid medicine, repeated abnormal hormone test results, or a suspected drug interaction. Steroids show up in pills, injections, inhalers, and creams, so mention all of them. If you have used a glucocorticoid steroid recently and develop repeated vomiting or diarrhea, call promptly, because this combination can signal a possible adrenal crisis and needs urgent clinical guidance.8
Call Poison Control at 1-800-222-1222 for an overdose, a medication mix-up, an unknown supplement exposure, or concerning symptoms after combining products. Do not use a home cortisol test kit to judge whether a situation is safe.
Call 911 now for collapse, loss of consciousness, a seizure, severe confusion, trouble breathing, or signs of shock like very low blood pressure. In someone with current or recent steroid use or known adrenal insufficiency, collapse, very low blood pressure, or persistent vomiting or diarrhea can signal a possible adrenal crisis and cannot wait for a home test. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
Suddenly stopping a steroid medicine after sustained use can be medically dangerous.8 This article gives no taper plan. Follow your prescriber’s exact instructions for stopping or changing any steroid medicine.
What to ask your prescriber
These are conversation starters, not instructions.
- Are we addressing a psychiatric symptom, a sleep problem, a medication effect, or a possible endocrine condition?
- What does the treatment you’re suggesting bind to directly, and which effects come from further down the chain?
- Would a cortisol or ACTH test actually answer a specific medical question for me right now?
- What timing, illness, or medication factor could throw off a hormone test result?
- Do any of my pills, injections, inhalers, or creams contain a glucocorticoid steroid?
- Could stopping a steroid or psychiatric medicine suddenly be unsafe for me?
- What should I watch for that would mean I should call before my next visit?
- When would an endocrine specialist evaluation make sense here?
Bottom line
CRH, ACTH, and cortisol are three different signals in three different compartments, not one stress hormone with three names, and that distinction is the whole reason “adrenal fatigue” testing does not hold up. Your brain is not a gas tank running low on one stress chemical, and the failed CRF1 drug trials show what happens when a treatment is built on that simpler story instead of the real one. Ask what a stress test actually measures, and what decision it can support, before treating a saliva result as an answer.
Two related signals worth knowing: norepinephrine drives the body’s other major alarm response, and neuropeptide Y is a stress-related signal covered in the next article in this series.
Frequently asked questions
Is CRH the same thing as cortisol?
No. CRH is a signal made in the hypothalamus and elsewhere. Cortisol is a steroid hormone made by the adrenal glands, several steps later in the same chain. ACTH sits between them.
Does anxiety mean my CRH is high?
No. Anxiety has many causes and involves many brain systems. Symptoms alone cannot identify what a specific brain chemical is doing.
Can a saliva cortisol test tell me which psychiatric medicine I need?
No. Saliva can measure cortisol at one point in time. It does not measure brain CRH activity and does not point to a specific medication choice.
What about “adrenal fatigue”?
It is not a validated medical condition, and no blood or saliva test can diagnose it.910 Fatigue itself is real and deserves a real evaluation, which may find sleep problems, anemia, thyroid disease, depression, or another explainable cause.
Why did the CRF1 blockers fail if CRH really matters in stress?
A biological system can be real and important without one specific receptor blocker helping a broad diagnosis. The wrong subgroup, dose, timing, or clinical model tested may explain the failures, and the specific drugs tested may simply not have been the right molecules. The negative trials still count as real evidence.
Does crinecerfont’s approval mean a CRH drug can now treat depression or anxiety?
No. Crinecerfont treats a hormone condition, congenital adrenal hyperplasia, where excess CRF1-and-ACTH signaling directly drives the problem. It has no psychiatric approval, and its success does not change what the psychiatric trials found.
Does a stressful childhood create one fixed, permanent hormone result?
No. Early adversity can shape stress biology at a group level, but outcomes vary widely based on genetics, relationships, safety, sleep, health, and later experience.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- Focus, Alarm, and the Chemical Behind Both
- The Resilience Chemical Nobody Can Measure
- Oxytocin Is Not the Love Hormone
References
1. Spencer RL, Deak T. A user’s guide to HPA-axis research. Physiol Behav. 2017. PMID: 27871862
2. Herman JP, et al. Regulation of the HPA stress response. Compr Physiol. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4867107/
3. Coric V, et al. Pexacerfont in generalized anxiety disorder. Depress Anxiety. 2010. PMID: 20455246
4. Binneman B, et al. CP-316,311 in major depression. Am J Psychiatry. 2008. PMID: 18413705
5. Dunlop BW, et al. GSK561679 in PTSD. Biol Psychiatry. 2017. PMID: 28793974
6. Schwandt ML, et al. Verucerfont in anxious alcohol-dependent women. Neuropsychopharmacology. 2016. PMID: 27109623
7. Kwako LE, et al. Pexacerfont in alcohol dependence. Neuropsychopharmacology. 2015. PMID: 25409596
8. Beuschlein F, et al. European Society of Endocrinology and Endocrine Society joint guideline on glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab. 2024. https://www.endocrine.org/clinical-practice-guidelines/glucocorticoid-induced-adrenal-insufficiency. PMID: 38714321
9. Endocrine Society. Adrenal Fatigue. Accessed August 31, 2026. https://www.endocrine.org/patient-engagement/endocrine-library/adrenal-fatigue
10. Cadegiani FA, Kater CE. Adrenal fatigue does not exist: a systematic review. BMC Endocr Disord. 2016. PMID: 27557747
11. Neurocrine Biosciences. FDA approval of Crenessity (crinecerfont) for congenital adrenal hyperplasia, December 2024.
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, share, combine, or change a psychiatric, steroid, or endocrine medicine because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.